Introduction {#tca13398-sec-0005}
============

The incidence and mortality of lung cancer ranks first among all malignancies worldwide.[1](#tca13398-bib-0001){ref-type="ref"} The prognosis of lung cancer patients is related to tumor stage, pathological type and concomitant disease, among which concomitant disease is an important factor affecting the prognosis.[2](#tca13398-bib-0002){ref-type="ref"} Diabetes mellitus is one of the most common endocrine diseases, mostly type 2 diabetes mellitus (type 2 DM). Epidemiological data show that the prevalence of type 2 DM is as high as 9.7%--11.6%, and type 2 DM is a risk factor for the occurrence, development and prognosis of various tumors.[3](#tca13398-bib-0003){ref-type="ref"}, [4](#tca13398-bib-0004){ref-type="ref"}, [5](#tca13398-bib-0005){ref-type="ref"} It has been reported in the literature that diabetes mellitus has a significant impact on the prognosis of gastric cancer, colorectal cancer, breast cancer and other malignant tumors,[6](#tca13398-bib-0006){ref-type="ref"}, [7](#tca13398-bib-0007){ref-type="ref"}, [8](#tca13398-bib-0008){ref-type="ref"} while there is no consistent conclusion on the impact of type 2 DM on the prognosis of lung cancer patients. Research investigating how pre‐existing diabetes mellitus influences lung cancer outcomes is critical to inform the proper care of these patients. The aim of this study was to examine the effects of type 2 DM at the time of cancer diagnosis on the overall survival (OS) of patients with NSCLC treated by surgery. In addition, we analyzed whether metformin could affect the prognosis of NSCLC patients with type 2 DM.

Methods {#tca13398-sec-0006}
=======

Sample setting and study population {#tca13398-sec-0007}
-----------------------------------

This retrospective study was conducted with approval of the Institutional Review Boards of the Anhui Medical University‐affiliated Anhui Provincial Hospital. Hospital, and departmental tumor registries were used to identify all patients undergoing curative resection of stages I‐IIIA NSCLC from January 2011 and August 2014. The patients were screened, and their hospital records were extracted if patients met the following criteria: (i) histopathologically proven NSCLC; (ii) no neoadjuvant therapy; (iii) no known distant metastasis; and (iv) R0 resection. Patients were excluded if they had: (i) palliative resection; (ii) type 1 diabetes mellitus; or (iii) incomplete medical records.

Patient characteristics {#tca13398-sec-0008}
-----------------------

The initial hospitalization during the years under study was identified as the index visit. Patients characteristics and clinical laboratory data during the index visit were extracted from hospital records, including the patient\'s age, sex, smoking history, surgical procedure, histological classification, pathological stage, tumor diameter, postoperative adjuvant radiotherapy and postoperative adjuvant chemotherapy. TNM staging was based on the International Association for Lung Cancer Research (IASLC) guidelines, eighth edition. The OS was calculated from the date of the operation for NSCLC until death from any cause. The disease‐free survival (DFS) was measured from the date of surgery to the date of locoregional recurrence, type 2 DM or death from any cause.

Type 2 DM recorded during the index visit was considered the main prognostic factor of interest in the study. The dependent variable in this analysis were OS and DFS. Of all patients, 662 (86.1%) patients were followed up until the end of 2019.

Statistical analysis {#tca13398-sec-0009}
--------------------

For quantitative variables, the *t*‐test was used for evaluating normally distributed data. Non‐normally distributed data were analyzed with the Mann‐Whitney test. Qualitative variables were examined with Pearson\'s χ2 test when appropriate. Data are expressed as the median and interquartile range. Survival curves for the two groups were estimated using the Kaplan‐Meier method and compared by a log‐rank test. Both univariate and multivariate Cox proportional hazards models were fitted to assess the association between type 2 DM with OS and DFS and to evaluate potential independent predictors of survival. The variables included in the Cox proportional hazards models were age, sex, smoking history, surgical procedure, tumor diameter, histological classification, TNM stage, type 2 DM, postoperative adjuvant chemotherapy, postoperative adjuvant radiotherapy and complications.

All analyses were performed using SPSS (IBM SPSS Statistics for Windows, Version 24.0).

Results {#tca13398-sec-0010}
=======

Baseline patient characteristics {#tca13398-sec-0011}
--------------------------------

A total of 769 patients with newly diagnosed NSCLC between January 2011 and August 2014 were included in the final analysis. The median follow‐up was 46 months (range: 0--108 months). The mean age of the study population was 67.8 years. Of all patients, 547 (71.1%) were males, and the majority (82.4%) did not have type 2 DM. Overall, 662 patients (86.1%) died by the end of 2019.

There were 276 stage IA cases, 95 stage IB cases, 129 stage IIA cases, 103 stage IIB cases and 166 stage IIIA cases. According to the type 2 DM, the patients were divided into the without diabetes mellitus group (*n* = 643; 16.4%; A group) and the diabetes mellitus group (*n* = 126; 83.6%; B group). The two groups were similar in terms of age, sex, smoking history, surgical procedure, tumor diameter, histological classification, TNM stage, type 2 DM, postoperative adjuvant chemotherapy, postoperative adjuvant radiotherapy and complications, with no significant differences (*P* \> 0.05) (Table [1](#tca13398-tbl-0001){ref-type="table"}).

###### 

Characteristics of NSCLC patients by type 2 diabetes mellitus (DM) (*n* = 769)

  Variable                          A group (*n* = 643)   B group (*n* = 126)     χ2     *P*‐value
  --------------------------------- --------------------- --------------------- ------- -----------
  **Sex**                                                                        1.878     0.171
  Male                              451                   96                            
  Female                            192                   30                            
  **Age (year)**                                                                 0.443     0.506
  ≤65                               428                   80                            
  \>65                              215                   46                            
  **Smoking history**                                                            0.017     0.896
  Yes                               241                   48                            
  No                                402                   78                            
  **Surgical procedure**                                                         0.186     0.666
  Lobectomy                         552                   110                           
  Pneumonectomy                     91                    16                            
  **Tumor diameter (cm)**                                                        0.122     0.727
  ≤3                                312                   59                            
  \>3                               331                   67                            
  **Histological classification**                                                0.628     0.890
  Adenocarcinoma                    360                   68                            
  Squamous cell carcinoma           241                   49                            
  Adenosquamous carcinoma           23                    6                             
  Other                             19                    3                             
  **TNM stage**                                                                  0.440     0.802
  I                                 312                   59                            
  II                                195                   37                            
  III                               136                   30                            
  **Postoperative chemotherapy**                                                 0.723     0.395
  Yes                               343                   62                            
  No                                300                   64                            
  **Postoperative radiotherapy**                                                 0.735     0.391
  Yes                               56                    14                            
  No                                587                   112                           
  **Complications**                                                              0.001     0.973
  Yes                               142                   28                            
  No                                501                   98                            

Prognostic factor analysis {#tca13398-sec-0012}
--------------------------

The results of the univariate analysis of factors associated with the OS in the patients are presented in Table [2](#tca13398-tbl-0002){ref-type="table"}. The univariate survival analysis revealed the following patient characteristics to be significant prognostic factors for poor survival: pneumonectomy, later stage, postoperative adjuvant chemotherapy, and type 2 DM. According to DFS calculations, the univariate survival analysis revealed the following patient characteristics to be significant prognostic factors for poor survival: pneumonectomy, later stage, postoperative adjuvant chemotherapy, postoperative adjuvant radiotherapy and type 2 DM. Detailed results are listed in Table [3](#tca13398-tbl-0003){ref-type="table"}.

###### 

Univariate and multivariate analyses of prognostic factors and overall survival (OS) in patients with NSCLC (*n* = 769)

                                    Univariate analysis   Multivariate analysis                                           
  --------------------------------- --------------------- ----------------------- ------- --------- --------------------- ---------
  **Sex**                                                                                   0.385            ---            0.625
  Male                              547                   44 ± 2.527              37.6%                                   
  Female                            222                   48 ± 4.723              41.6%                                   
  **Age (year)**                                                                            0.432            ---            0.202
  ≤65                               508                   47 ± 2.582              38.9%                                   
  \>65                              261                   46 ± 4.106              39.3%                                   
  **Smoking history**                                                                       0.336            ---            0.451
  Yes                               289                   42 ± 2.852              35.0%                                   
  No                                480                   48 ± 2.850              41.1%                                   
  **Surgical procedure**                                                                    0.003    1.333(1.070--1.662)    0.010
  Lobectomy                         662                   48 ± 2.571              40.6%                                   
  Pneumonectomy                     107                   36 ± 3.775              27.5%                                   
  **Tumor diameter (cm)**                                                                   0.296            ---            0.234
  ≤3                                335                   47 ± 3.174              39.5%                                   
  \>3                               434                   46 ± 2.729              38.1%                                   
  **Histological classification**                                                           0.073            ---            0.148
  Adenocarcinoma                    428                   48 ± 3.644              41.8%                                   
  Squamous‐cell carcinoma           290                   45 ± 2.632              36.0%                                   
  Adenosquamous carcinoma           29                    33 ± 0.893              24.1%                                   
  Other                             22                    31 ± 11.770             21.2%                                   
  **TNM stage**                                                                            \<0.001   1.240(1.124--1.369)   \<0.001
  I                                 371                   55 ± 2.686              45.2%                                   
  II                                232                   44 ± 4.930              37.6%                                   
  III                               166                   37 ± 2.625              26.3%                                   
  **Type 2 DM**                                                                             0.045    0.787(0.641--0.967)    0.023
  Yes                               126                   36 ± 4.370              33.3%                                   
  No                                643                   48 ± 2.236              40.6%                                   
  **Postoperative chemotherapy**                                                           \<0.001           ---            0.112
  Yes                               405                   39 ± 1.888              33.4%                                   
  No                                364                   56 ± 3.355              45.0%                                   
  **Postoperative radiotherapy**                                                            0.055            ---            0.994
  Yes                               70                    36 ± 2.007              27.9%                                   
  No                                699                   48 ± 2.154              39.9%                                   
  **Complications**                                                                         0.067                           0.074
  Yes                               170                   37 ± 2.944              32.3%                                   
  No                                599                   48 ± 2.285              40.5%                                   

###### 

Univariate and multivariate analyses of prognostic factors and disease‐free survival (DFS) in patients with NSCLC (*n* = 769)

                                    Univariate analysis   Multivariate analysis                                           
  --------------------------------- --------------------- ----------------------- ------- --------- --------------------- ---------
  **Sex**                                                                                   0.383            ---            0.597
  Male                              547                   36 ± 2.454              12.6%                                   
  Female                            222                   41 ± 3.765              17.3%                                   
  **Age (year)**                                                                            0.686            ---            0.402
  ≤65                               508                   37 ± 2.202              13.2%                                   
  \>65                              261                   38 ± 3.742              15.8%                                   
  **Smoking history**                                                                       0.265            ---            0.368
  Yes                               289                   34 ± 2.987              11.5%                                   
  No                                480                   39 ± 2.878              15.5%                                   
  **Surgical procedure**                                                                    0.009    1.333(1.070--1.662)    0.030
  Lobectomy                         662                   39 ± 2.298              14.6%                                   
  Pneumonectomy                     107                   26 ± 3.995              10.2%                                   
  **Tumor diameter (cm)**                                                                   0.265            ---            0.238
  ≤3                                335                   38 ± 2.916              15.2%                                   
  \>3                               434                   36 ± 2.811              13.0%                                   
  **Histological classification**                                                           0.114            ---            0.148
  Adenocarcinoma                    428                   42 ± 2.917              15.4%                                   
  Squamous‐cell carcinoma           290                   36 ± 2.305              13.8%                                   
  Adenosquamous carcinoma           29                    21 ± 15.249             3.4%                                    
  Other                             22                    19 ± 12.181             5.6%                                    
  **TNM stage**                                                                            \<0.001   1.240(1.124--1.369)   \<0.001
  I                                 371                   45 ± 2.353              16.9%                                   
  II                                232                   37 ± 4.135              14.5%                                   
  III                               166                   25 ± 2.898              6.7%                                    
  **Type 2 DM**                                                                             0.023    0.787(0.641--0.967)    0.013
  Yes                               126                   25 ± 5.241              10.2%                                   
  No                                643                   38 ± 2.091              14.7%                                   
  **Postoperative chemotherapy**                                                           \<0.001           ---            0.138
  Yes                               405                   30 ± 2.277              10.4%                                   
  No                                364                   46 ± 2.171              18.0%                                   
  **Postoperative radiotherapy**                                                            0.035            ---            0.877
  Yes                               70                    24 ± 1.744              10.2%                                   
  No                                699                   38 ± 1.973              14.4%                                   
  **Complications**                                                                         0.115                           0.087
  Yes                               170                   28 ± 4.485              14.9%                                   
  No                                599                   39 ± 2.431              13.7%                                   

The further multivariate analysis identified that, for the NSCLC patients, type 2 DM (*P* = 0.023), TNM stage (*P* \< 0.001) and surgical procedure (*P* = 0.010) were independent factors associated with OS (Table [2](#tca13398-tbl-0002){ref-type="table"}), while the type 2 DM (*P* = 0.013), TNM stage (*P* \< 0.001) and surgical procedure (*P* = 0.030) were identified as independent prognostic factor for DFS (Table [3](#tca13398-tbl-0003){ref-type="table"}).

The Kaplan‐Meier curve for OS displayed a statistically significant association with survival and type 2 DM (Fig [1](#tca13398-fig-0001){ref-type="fig"}a). The one‐, three‐, and five‐year OS rates for patients with and without type 2 DM were 86.1% versus 89.6%, 49.5% versus 62.4%, and 33.3% versus 40.6%, respectively, and the corresponding DFS rates were 73.6% versus 79.9%, 41.4% versus 51.9%, and 10.2% versus 13.3%, respectively (Fig [1](#tca13398-fig-0001){ref-type="fig"}b).

![Kaplan‐Meier survival curves for A group and B group. (**a**) The median overall survival (OS) was significantly better in the A group. (**b**) The patients without type 2 DM (A group) had better median disease‐free survival (DFS). (**a**) (![](TCA-11-1309-g003.jpg "image")) B group, (![](TCA-11-1309-g004.jpg "image")) A group, (![](TCA-11-1309-g005.jpg "image")) B group censored, (![](TCA-11-1309-g006.jpg "image")) A group censored. (**b**) (![](TCA-11-1309-g007.jpg "image")) B group, (![](TCA-11-1309-g008.jpg "image")) A group, (![](TCA-11-1309-g009.jpg "image")) B group censored, (![](TCA-11-1309-g010.jpg "image")) A group censored.](TCA-11-1309-g001){#tca13398-fig-0001}

Further analyses {#tca13398-sec-0013}
----------------

According to whether metformin was used in group B, the patients were divided into the metformin group (*n* = 35; 27.8%) and the nonmetformin group (*n* = 91; 72.2%). The two groups were similar in terms of age, sex, smoking history, surgical procedure, tumor diameter, histological classification, TNM stage, type 2 DM, postoperative adjuvant chemotherapy, postoperative adjuvant radiotherapy and complications, with no significant differences (*P* \> 0.05) (Table [4](#tca13398-tbl-0004){ref-type="table"}).

###### 

Characteristics of NSCLC patients with type 2 DM by metformin (*n* = 126)

  Variable                          Metformin group (*n* = 35)   Nonmetformin group (*n* = 91)    χ^2^    *P‐*value
  --------------------------------- ---------------------------- ------------------------------- ------- -----------
  **Sex**                                                                                         1.187     0.276
  Male                              29                           67                                      
  Female                            6                            24                                      
  **Age (year)**                                                                                  0.008     0.927
  ≤65                               22                           58                                      
  \>65                              13                           33                                      
  **Smoking history**                                                                             0.913     0.339
  Yes                               11                           37                                      
  No                                24                           54                                      
  **Surgical procedure**                                                                          1.349     0.245
  Lobectomy                         33                           77                                      
  Pneumonectomy                     2                            14                                      
  **Tumor diameter**                                                                              0.096     0.757
  ≤3                                18                           44                                      
  \>3                               17                           47                                      
  **Histological classification**                                                                 2.028     0.567
  Adenocarcinoma                    19                           49                                      
  Squamous‐cell carcinoma           22                           37                                      
  Adenosquamous carcinoma           3                            3                                       
  Other                             1                            2                                       
  **TNM stage**                                                                                   0.397     0.820
  I                                 17                           42                                      
  II                                11                           26                                      
  III                               7                            23                                      
  **Postoperative chemotherapy**                                                                  1.643     0.200
  Yes                               14                           48                                      
  No                                21                           43                                      
  **Postoperative radiotherapy**                                                                  0.061     0.806
  Yes                               3                            11                                      
  No                                32                           80                                      
  **Complications**                                                                               0.138     0.710
  Yes                               7                            21                                      
  No                                28                           70                                      

The univariate analyses were conducted, and the detailed result was that the patients with young age, later stage, postoperative adjuvant chemotherapy, postoperative adjuvant radiotherapy, complications and metformin use have a worse OS and DFS. Detailed results are listed in Tables [5](#tca13398-tbl-0005){ref-type="table"} and [6](#tca13398-tbl-0006){ref-type="table"}. The further multivariate analysis identified that the TNM stage (*P* \< 0.001) and metformin use (*P* = 0.016) were independent factors associated with OS (Table [5](#tca13398-tbl-0005){ref-type="table"}), while the TNM stage (*P* \< 0.001) and metformin use (*P* = 0.019) were identified as independent prognostic factor for DFS (Table [6](#tca13398-tbl-0006){ref-type="table"}).

###### 

Univariate and multivariate analyses of prognostic factors and overall survival (OS) in patients with NSCLC with type 2 DM (*n* = 126)

                                    Univariate analysis   Multivariate analysis                                         
  --------------------------------- --------------------- ----------------------- ------- ------- --------------------- ---------
  **Sex**                                                                                  0.497           ---            0.927
  Male                              96                    36 ± 6.735              32.3%                                 
  Female                            30                    36 ± 4.397              23.2%                                 
  **Age (year)**                                                                           0.037           ---            0.171
  ≤65                               80                    36 ± 3.732              26.7%                                 
  \>65                              46                    46 ± 8.261              34.6%                                 
  **Smoking history**                                                                      0.435           ---            0.496
  Yes                               48                    43 ± 10.590             37.4%                                 
  No                                78                    36 ± 2.232              25.7%                                 
  **Surgical procedure**                                                                   0.223           ---            0.992
  Lobectomy                         110                   37 ± 5.649              31.5%                                 
  Pneumonectomy                     16                    33 ± 11.686             22.2%                                 
  **Tumor diameter (cm)**                                                                  0.247           ---            0.694
  ≤3                                62                    46 ± 7.329              30.8%                                 
  \>3                               64                    36 ± 3.806              29.7%                                 
  **Histological classification**                                                          0.649           ---            0.552
  Adenocarcinoma                    68                    43 ± 5.817              34.1%                                 
  Squamous‐cell carcinoma           49                    36 ± 5.352              27.8%                                 
  Adenosquamous carcinoma           6                     26 ± 3.674              0.0%                                  
  Other                             3                     23 ± 4.899              0.0%                                  
  **TNM stage**                                                                            0.002   1.582(1.099--2.546)   \<0.001
  I                                 59                    54 ± 7.893              43.0%                                 
  II                                37                    30 ± 4.198              22.0%                                 
  III                               30                    24 ± 5.613              14.4%                                 
  **Metformin**                                                                            0.039   1.673(1.099--2.546)    0.016
  Yes                               35                    49 ± 7.644              40.4%                                 
  No                                91                    33 ± 3.031              26.0%                                 
  **Postoperative chemotherapy**                                                           0.008           ---            0.851
  Yes                               62                    30 ± 3.749              24.2%                                 
  No                                64                    48 ± 8.208              36.3%                                 
  **Postoperative radiotherapy**                                                           0.004           ---            0.112
  Yes                               14                    24 ± 5.727              0.0%                                  
  No                                112                   39 ± 5.967              34.0%                                 
  **Complications**                                                                        0.023                          0.105
  Yes                               28                    30 ± 2.433              9.5%                                  
  No                                98                    42 ± 5.750              34.7%                                 

###### 

Univariate and multivariate analyses of prognostic factors and DFS in patients with NSCLC with type 2 DM (*n* = 126)

                                    Univariate analysis   Multivariate analysis                                         
  --------------------------------- --------------------- ----------------------- ------- ------- --------------------- ---------
  **Sex**                                                                                  0.546           ---            0.986
  Male                              96                    25 ± 6.772              9.0%                                  
  Female                            30                    25 ± 4.603              0.0%                                  
  **Age (year)**                                                                           0.024           ---            0.126
  ≤65                               80                    24 ± 4.295              2.9%                                  
  \>65                              46                    34 ± 12.360             19.9%                                 
  **Smoking history**                                                                      0.511           ---            0.551
  Yes                               48                    34 ± 10.314             10.3%                                 
  No                                78                    24 ± 2.282              6.7%                                  
  **Surgical procedure**                                                                   0.254           ---            0.983
  Lobectomy                         110                   27 ± 5.265              8.2%                                  
  Pneumonectomy                     16                    21 ± 5.196              7.5%                                  
  **Tumor diameter (cm)**                                                                  0.202           ---            0.820
  ≤3                                62                    35 ± 7.557              13.0%                                 
  \>3                               64                    24 ± 3.858              3.8%                                  
  **Histological classification**                                                          0.540           ---            0.401
  Adenocarcinoma                    68                    34 ± 7.285              13.8%                                 
  Squamous cell carcinoma           49                    24 ± 5.261              9.5%                                  
  Adenosquamous carcinoma           6                     14 ± 3.674              0.0%                                  
  Other                             3                     11 ± 0.816              0.0%                                  
  **TNM stage**                                                                            0.002   1.534(1.208--1.948)   \<0.001
  I                                 59                    45 ± 7.879              14.8%                                 
  II                                37                    18 ± 4.044              3.2%                                  
  III                               30                    16 ± 3.134              0.0%                                  
  **Metformin**                                                                            0.041   1.649(1.649--2.508)    0.019
  Yes                               35                    44 ± 7.655              12.7%                                 
  No                                91                    21 ± 2.916              6.1%                                  
  **Postoperative chemotherapy**                                                           0.009           ---            0.976
  Yes                               62                    18 ± 2.625              2.1%                                  
  No                                64                    38 ± 7.638              13.8%                                 
  **Postoperative radiotherapy**                                                           0.012           ---            0.216
  Yes                               14                    17 ± 4.640              0.0%                                  
  No                                112                   30 ± 6.193              9.1%                                  
  **Complications**                                                                        0.017                          0.065
  Yes                               28                    18 ± 3.603              5.5%                                  
  No                                98                    34 ± 6.553              9.0%                                  

The Kaplan‐Meier curve for OS displayed a statistically significant association between survival and metformin (Fig [2](#tca13398-fig-0002){ref-type="fig"}a). The one‐, three‐, and five‐year survival rates for patients treated with and without metformin were 91.4% versus 84.0%, 65.2% versus 42.9%, and 43.5% versus 28.9%, respectively, and the corresponding DFS rates were 85.7% versus 68.7%, 53.8% versus 36.2%, and 12.7% versus 6.1%, respectively (Fig [2](#tca13398-fig-0002){ref-type="fig"}b).

![Kaplan‐Meier survival curves for metformin users and nonusers. (**a**) The median overall survival was significantly better in the metformin user group. (**b**) The patients using metformin had better median disease‐free survival (DFS). (**a**) (![](TCA-11-1309-g011.jpg "image")) Metformin group, (![](TCA-11-1309-g012.jpg "image")) Nonmetformin group, (![](TCA-11-1309-g013.jpg "image")) Metformin group censored, (![](TCA-11-1309-g014.jpg "image")) Nonmetformin group censored. (**b**) (![](TCA-11-1309-g015.jpg "image")) Metformin group, (![](TCA-11-1309-g016.jpg "image")) Nonmetformin group, (![](TCA-11-1309-g017.jpg "image")) Metformin group censored, (![](TCA-11-1309-g018.jpg "image")) Nonmetformin group censored.](TCA-11-1309-g002){#tca13398-fig-0002}

Discussion {#tca13398-sec-0014}
==========

Diabetes mellitus is one of the most common endocrine diseases.[9](#tca13398-bib-0009){ref-type="ref"} As the world\'s population ages, the number of patients with lung cancer and diabetes mellitus appear to be on the rise. The literature reports that diabetes mellitus has a significant impact on the prognosis of gastric cancer, colorectal cancer, breast cancer and other malignant tumors.[6](#tca13398-bib-0006){ref-type="ref"}, [7](#tca13398-bib-0007){ref-type="ref"}, [8](#tca13398-bib-0008){ref-type="ref"} However, there are few studies on the impact of diabetes mellitus on lung cancer, and there are differences in their findings.[10](#tca13398-bib-0010){ref-type="ref"}, [11](#tca13398-bib-0011){ref-type="ref"}, [12](#tca13398-bib-0012){ref-type="ref"} At present, most of the studies on lung cancer with diabetes mellitus are on patients with advanced disease who are receiving chemoradiotherapy, while there are relatively few studies on patients with lung cancer and diabetes mellitus undergoing surgery in the early and middle stages.[13](#tca13398-bib-0013){ref-type="ref"}, [14](#tca13398-bib-0014){ref-type="ref"}, [15](#tca13398-bib-0015){ref-type="ref"} This study found that type 2 DM was significantly associated with long‐term survival in patients with NSCLC who underwent surgery, and long‐term survival was significantly lower in patients with type 2 DM. In addition, further studies have found that patients with NSCLC using metformin, a hypoglycaemic agent, have better long‐term survival than patients with NSCLC using nonmetformin hypoglycaemic agents.

This study found that NSCLC patients with type 2 DM who underwent radical surgery had a worse five‐year survival than NSCLC patients without type 2 DM. Inal *et al*. found that 442 patients with advanced NSCLC who received chemotherapy had better survival than NSCLC patients without diabetes mellitus, and diabetes mellitus was an independent prognostic factor for advanced NSCLC patients.[16](#tca13398-bib-0016){ref-type="ref"} Peter *et al*. analyzed 1852 patients with advanced lung cancer from three databases, HUNT, PEG and NLCB. Among them, 84 patients had lung cancer and diabetes mellitus and 1768 patients had lung cancer without diabetes mellitus. Patients with advanced lung cancer and diabetes mellitus have worse survival than patients with advanced lung cancer without diabetes mellitus, and multivariate analysis found that diabetes mellitus is an independent prognostic factor for patients with advanced lung cancer.[17](#tca13398-bib-0017){ref-type="ref"} This is similar to our findings.

With regard to the causes of type 2 DM that affect the prognosis of NSCLC patients, the current study believes that, first, insulin and IGF‐1 activate pathways such as P13K/Akt kinase and Ras/MAP kinase, which stimulate tumor cell proliferation, metastasis, and progression. The P13K/Akt kinase pathway plays an important role in tumor resistance. In addition, studies have shown that inhibition of the PI3K/Akt kinase pathway can increase the killing of tumor cells by chemotherapy and radiotherapy. Insulin resistance in type 2 DM leads to hyperinsulinaemia, and hyperinsulinaemia indirectly affects the carcinogenic effects of IGF‐1. High insulin enhances tumor risk by inhibiting the binding of IGF‐1 to proteins, thereby increasing the bioavailability of IGF‐1.[18](#tca13398-bib-0018){ref-type="ref"} Second, hyperinsulinaemia produces too much peroxide by destroying the mitochondria. Oxidative stress caused by peroxide can cause a series of complications and increase the DNA damage of the cells, thereby increasing the possibility of damage to the body caused by mutations in tumor cell‐related genes in patients. In addition, the metabolism of tumor cells is completed under anaerobic conditions, so the demand for glucose is great, and the hyperglycaemia in diabetic patients creates better conditions for the survival of tumor cells.[19](#tca13398-bib-0019){ref-type="ref"} Finally, the inflammatory response is accompanied by the whole process of tumorigenesis and development, and various signaling pathways, such as interleukin‐6, TNF‐a and STAT3, can activate inflammation‐related responses and affect the progression of the tumor.[20](#tca13398-bib-0020){ref-type="ref"}

Our study divided the patients with diabetes mellitus into the metformin group and the nonmetformin group. Through multivariate and survival analysis, we found that patients with metformin have longer survival and that metformin use is an independent prognostic factors for NSCLC patients with type 2 DM. A study by Dhillon *et al*. of 409 patients with stage I NSCLC with diabetes mellitus found that patients taking metformin had longer survival and that metformin was an independent prognostic factor for NSCLC with diabetes mellitus.[15](#tca13398-bib-0015){ref-type="ref"} Tseng *et al*. studied the survival of 15 414 patients who had never used metformin and 280 159 patients who had used metformin. Patients with lung cancer and type 2 DM who used metformin had better survival than type 2 DM patients who did not use metformin.[21](#tca13398-bib-0021){ref-type="ref"}

Metformin primarily reduces circulating glucose levels in patients with AMPK activation mediated by liver kinase B1, a tumor suppressor protein that responds during metabolic stress.[22](#tca13398-bib-0022){ref-type="ref"} The anticancer effect of metformin inhibits mammalian target of rapamycin via the hepatic kinase B1/AMPK pathway, leading to protein synthesis, cell cycle arrest and apoptosis inhibition.[23](#tca13398-bib-0023){ref-type="ref"} A recent study suggested that AMPK activation may promote cell growth,[24](#tca13398-bib-0024){ref-type="ref"} but metformin also inhibits mammalian rapamycin targets through the GTP‐activated protein‐dependent pathway.[25](#tca13398-bib-0025){ref-type="ref"} Since elevated levels of insulin‐like growth factor 1 (IGF‐1) may be carcinogenic, a study explored the role of metformin in reducing IGF‐1‐mediated tumorigenesis, demonstrating that metformin reduces IGF‐1 levels independent of the AMPK pathway. In mice treated with metformin, it has been shown that activation of the protein‐dependent pathway by GTPase and regulation of receptor tyrosine kinase activity can significantly reduce tumorigenesis, regardless of the decrease in IGF‐1 levels.[26](#tca13398-bib-0026){ref-type="ref"} It has also been reported that metformin clinically enhances the response of NSCLC cells to radiotherapy through the AMPK‐dependent pathway.[27](#tca13398-bib-0027){ref-type="ref"}, [28](#tca13398-bib-0028){ref-type="ref"} Metformin has been confirmed as a first‐line drug for the treatment of diabetes mellitus. However, its antitumour mechanism remains unclear, and further experimental research is needed. At the same time, it also provides new ideas and methods for the treatment of lung cancer. In addition, many studies are aimed at patients with diabetes mellitus with lung cancer. For nondiabetic lung cancer patients, the antitumour effect of metformin needs further study.

Univariate and multivariate analyses of the study found that the five‐year survival rates after lobectomy and pneumonectomy were 41.0% and 25.8%, respectively, and the surgical approach was an independent prognostic factor for patients with NSCLC. There are some potential explanations for this difference. First, in this study, a total of 658 patients with lobectomy accounted for 85.6% of the entire group, and patients with pneumonectomy accounted for 14.4%, so there was a certain statistical bias. Second, the pathological stage of patients with pneumonectomy is generally late, so the patient survival is generally short and the prognosis is poor. Finally, patients with pneumonectomy are more likely to have multiple organ failure, such as respiratory and heart failure, than patients with lobectomy, thus affecting the prognosis of patients.

This study has the following shortcomings. First, because this study is a retrospective study, it is not possible to accurately assess the severity of diabetes and glycaemic control in postoperative patients. In addition, the study used a randomized fasting blood glucose of more than 126 mg/dL and a previous diagnosis of type 2 DM by endocrinologists as the basis for diagnosis, so there is a diagnostic bias. Second, this study did not specifically calculate the specific dose of metformin in patients and the dose may affect the antitumor effect of metformin. Third, there are no other factors associated with the complications associated with chronic diseases and surgery that may affect surgical outcomes and long‐term survival.

In conclusion, type 2 DM was independently associated with a significantly higher risk of all‐cause mortality in patients with NSCLC. To further extend the current understanding, future studies applying large prognostic evaluations with longer follow‐ups to confirm the prognostic utility of type 2 DM are needed. In addition, the antitumor effect and mechanism of metformin remain to be further studied.
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